JF
ABOS icon

Jump Financial’s Acumen Pharmaceuticals ABOS Stock Holding History

Jump Financial’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,200
Closed -$52.6K – 1583
2024
Q3 		$52.6K Sell
21,200
-28,167
-57% -$76.4K ﹤0.01% 1555
2024
Q2 		$119K Buy
49,367
+25,416
+106% +$80.9K ﹤0.01% 1626
2024
Q1 		$97K Sell
23,951
-79,049
-77% -$298K ﹤0.01% 1793
2023
Q4 		$396K Buy
103,000
+69,100
+204% +$205K 0.01% 1189
2023
Q3 		$141K Buy
+33,900
New +$209K 0.01% 1623
2023
Q2 		– Sell
-10,183
Closed -$41.3K – 1748
2023
Q1 		$41.3K Sell
10,183
-11,056
-52% -$57.7K ﹤0.01% 1501
2022
Q4 		$115K Buy
+21,239
New +$143K 0.01% 1405
2022
Q1 		– Sell
-20,097
Closed -$136K – 1500
2021
Q4 		$136K Buy
+20,097
New +$221K 0.01% 1178

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Jump Financial's ABOS Position: Q4 2024 in Review

Jump Financial sold out of Acumen Pharmaceuticals (ABOS) in Q4 2024, closing a stake of 21,200 shares — an estimated $52.6K sold.

Jump Financial first reported a position in ABOS in Q4 2021 and held it in 8 quarters. The position peaked at $396K in Q4 2023. 80 funds tracked by Wall St. Rank hold ABOS as of Q4 2024.

  • Jump Financial reported no remaining Acumen Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Jump Financial sold 21,200 Acumen Pharmaceuticals shares in Q4 2024, an estimated $52.6K.
  • Jump Financial first reported a position in Acumen Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Jump Financial's Acumen Pharmaceuticals position peaked at $396K in Q4 2023.
  • 80 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q4 2024.

Based on Jump Financial's 13F filing for Q4 2024, filed 13 Feb 2025.